Biocon Ltd.
Fundamentals
- Market cap
- ₹67,454 cr
- P/E
- 174.93×
- ROE
- 4.68%
- Debt / equity
- 0.82
- Div yield
- 0.12%
- 52-week range
- 331.00 — 440.40
Company snapshot
Biocon Ltd.
Pharmaceuticals
₹71,821 cr
P/E 186.26×
Latest quarter · Mar 2026
Sales₹4,517 cr
Net profit₹199 cr
Op. margin+22.6%
EPS₹0.78
Strength & growth
Debt / equity0.44×
Current ratio1.22×
Sales CAGR+17.6%
EPS CAGR−6.9%
The timeline — 3 notes on Biocon Ltd.
July 2026
- 16 Jul 26 · 8:44 AM IST Brief Brief · Large cap
EMA clears Biocon's new Semglee fill line in Malaysia
European nod expands capacity for biosimilar insulin glargine at Johor plant; shipments to begin Q2 FY27, financial impact undisclosed.
- 15 Jul 26 · 1:30 PM IST Alert Alert · Large cap
Mylan dumps its 5.64% Biocon stake in ₹4,000 cr open-market sale
Long-term biosimilars partner sells entire 9.19 crore shares in a single day. Exit removes a strategic investor and creates a supply overhang.